Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
iTonic Holdings Ltd. (ITOC)
Beijing, CN
iTonic Holdings Ltd., a healthcare solutions firm, specializes in the development and commercialization of software and devices for brachytherapy. Its advanced proprietary treatment planning system centers on radioactive particle implantation, a form of radiotherapy employed in cancer treatment to precisely position radioactive sources within patients, thereby eradicating malignant cells and reducing tumor size. Key among its offerings is FTTPS, a sophisticated treatment planning system engineered for diverse malignant tumors. This system excels at defining the target volume, determining the prescribed dose, establishing safety margins for organs at risk, and formulating a precise dose distribution plan essential for brachytherapy patients. Founded in Beijing, China, in 1998, the company operated as Pheton Holdings Ltd. until its rebranding to iTonic Holdings Ltd. in January 2026. iTonic Holdings Ltd. functions as a subsidiary of ZJW (BVI) LTD.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | -17.31% | -14.77% | -32.13% | -28.74% | -32.13% | -32.13% | -32.13% | -32.13% | -32.13% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
-
Revenue growth Medical - Specialties: +8.3%+16.7% ★ Q4'25: +25.9% (vs Q4'23)
-
EPS growth Medical - Specialties: +10.1%-516.6% Q4'25: -1,551.4% (vs Q4'23)
-
FCF margin FCF growth · Medical - Specialties: +51.3%-1,210.6% Q4'25: -88.9% (vs Q4'23)
-
EBIT margin Medical - Specialties: +12.6%-991.7% Q4'25: -681.9% (vs Q4'23)
-
ROIC Medical - Specialties: +6.6%-97.1% Q4'25: -232.5% (vs Q4'23)
-
Share dilution Medical - Specialties: 0.0%+26.1% Q4'25: +15.9% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Medical - Specialties: -0.39×-0.03× Q4'25: -0.01× (vs Q4'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-28 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-27 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-26 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-22 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-21 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-20 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-19 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-18 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-15 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-14 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-13 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-12 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-11 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-08 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-07 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-06 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-05 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-04 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-01 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-30 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-29 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-28 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-27 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-24 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-23 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-22 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-21 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-20 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-17 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-16 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
Owner Earnings
Ownership Overview
No beneficial ownership filings recorded.
Institutional Activity (13F)
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | XTX TOPCO LTD | 48.3K -34.5K (-41.7%) | 16.9K -17.9K (-51.5%) | 0.32% -0.230 pp | 0.00% -0.001 pp | USD0.43 -18.6% | 3 qtrs — |
| 2 | CITADEL ADVISORS LLC | 29.6K +16.5K (+126.5%) | 10.3K +4.9K (+88.4%) | 0.20% +0.110 pp | 0.00% +0.000 pp | USD0.38 -7.9% | 2 qtrs — |
| 3 | POINT72 ASSET MANAGEMENT, L.P. | 10.9K +— (+0.0%) | 3.8K -769.0 (-16.8%) | 0.07% +0.000 pp | 0.00% +0.000 pp | USD0.42 -16.7% | 2 qtrs — |
| 4 | — | 5.2K +5.2K (+100.0%) | 2.0K +2.0K (+100.0%) | 0.04% +0.035 pp | 0.00% +0.001 pp | USD0.35 +0.0% | 1 qtrs NEW |
| 5 | NATIONAL BANK OF CANADA /FI/ | 1.8K +— (+0.0%) | 630.00 -128.0 (-16.9%) | 0.01% +0.000 pp | 0.00% +0.000 pp | USD0.44 -20.5% | 3 qtrs — |
| 6 | BLACKROCK, INC. | 618.00 +— (+0.0%) | 216.00 -44.0 (-16.9%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD0.44 -20.5% | 4 qtrs — |
| 7 | MORGAN STANLEY | 473.00 +— (+0.0%) | 166.00 -33.0 (-16.6%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD0.44 -20.5% | 4 qtrs — |
| 8 | COMPAGNIE LOMBARD ODIER SCMA | 140.00 +— (+0.0%) | 49.00 -11.0 (-18.3%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD0.44 -20.5% | 4 qtrs — |
| 9 | TWO SIGMA SECURITIES, LLC | — -15.8K (-100.0%) | — -6.6K (-100.0%) | 0.00% -0.105 pp | 0.00% -0.001 pp | USD— | 2 qtrs SOLD |
| 10 | TWO SIGMA INVESTMENTS, LP | — -10.9K (-100.0%) | — -4.6K (-100.0%) | 0.00% -0.073 pp | 0.00% +0.000 pp | USD— | 2 qtrs SOLD |
| 11 | UBS GROUP AG | — -108.0K (-100.0%) | — -45.5K (-100.0%) | 0.00% -0.720 pp | 0.00% +0.000 pp | USD— | 6 qtrs SOLD |
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-09-06 | Zhang Pengfei | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-09-06 | Zhang Jianfei | Director / Officer / 10% Owner | — | — | Class A Ordinary Shares, par value $0.0001 per share | 0 | 0.00 | — | 33,346 | D | ↗ |
| 2024-09-06 | Li Zhixin | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Jianfei Zhang | CEO & Chairman of the Board | — | male |
| Zhixin Li | Chief Financial Officer | — | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for ITOC
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
